Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) and Oncocyte (NASDAQ:IMDX – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.
Profitability
This table compares Aclaris Therapeutics and Oncocyte’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aclaris Therapeutics | -921.50% | -61.65% | -42.41% |
| Oncocyte | -2,955.63% | N/A | -107.52% |
Earnings and Valuation
This table compares Aclaris Therapeutics and Oncocyte”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aclaris Therapeutics | $7.83 million | 75.07 | -$64.92 million | ($0.58) | -7.25 |
| Oncocyte | $4.05 million | 20.00 | -$50.22 million | ($1.49) | -1.66 |
Oncocyte has lower revenue, but higher earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Oncocyte, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Aclaris Therapeutics has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Comparatively, Oncocyte has a beta of 1.9, meaning that its share price is 90% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and recommmendations for Aclaris Therapeutics and Oncocyte, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aclaris Therapeutics | 1 | 0 | 5 | 3 | 3.11 |
| Oncocyte | 1 | 0 | 2 | 0 | 2.33 |
Aclaris Therapeutics currently has a consensus price target of $11.33, indicating a potential upside of 169.58%. Oncocyte has a consensus price target of $10.50, indicating a potential upside of 324.24%. Given Oncocyte’s higher possible upside, analysts clearly believe Oncocyte is more favorable than Aclaris Therapeutics.
Institutional and Insider Ownership
98.3% of Aclaris Therapeutics shares are held by institutional investors. Comparatively, 55.3% of Oncocyte shares are held by institutional investors. 4.8% of Aclaris Therapeutics shares are held by company insiders. Comparatively, 2.2% of Oncocyte shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Aclaris Therapeutics beats Oncocyte on 10 of the 15 factors compared between the two stocks.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
About Oncocyte
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
